UPDATE 2-New drugs, currency lift Bayer's third quarter core profit
* Q3 EBITDA 2.52 bln eur vs Reuters poll avg 2.31 bln
* Eylea anti-blindness treatment sales jump 69 percent
* Shares up 1.3 percent, outperforming the DAX (Adds details on CropScience unit, forex effects)
By Ludwig Burger
FRANKFURT, Oct 29 (Reuters) - German drugmaker Bayer's core earnings jumped 28 percent in the third quarter, bolstered by sales of new drugs, the $14 billion purchase of Merck & Co's consumer health business and positive currency effects.
Earnings before interest, taxes, depreciation and amortisation (EBITDA), excluding one-offs, rose to 2.52 billion euros ($2.8 billion), above market predictions of 2.31 billion euros as the crop protection business fared better than expected
Shares in Bayer gained 1.3 percent while Germany's blue-chip index DAX was little changed.
Analysts said the CropScience division, a pesticides and seeds business, proved more resilient than feared after results at rival pesticides makers BASF, DuPont and Syngenta took a hit from a weak Brazilian market.
Bayer Chief Executive Marijn Dekkers pointed to 4-6 percent organic growth in some markets outside Latin America. Continuación...